 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
| Hee-Jeong Cho, Sang-Kyung Seo, Dong Won Baek, Sung-Woo Park, Yoo-Jin Lee, Sang-Kyun Sohn, Ho-Sup Lee, Won Sik Lee, Ji Hyun Lee, Sung Hyun Kim, Joon-Ho Moon |
|
J Yeungnam Med Sci. 2018;35(1):76-83. Published online June 30, 2018 DOI: https://doi.org/10.12701/yujm.2018.35.1.76 |
|
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen Yeungnam University Journal of Medicine. 2018;35(1):76-83  Outcomes between frontline and salvage bortezomib-based regimens in elderly patients with multiple myeloma Clinical Lymphoma Myeloma and Leukemia. 2015;15:e263 Clinical impact of depth of response on 3 months after starting chemotherapy and cumulative dose of bortezomib on survival in elderly patients with multiple myeloma who treated with bortezomib combined melphalan plus prednisolone; How to improve survival rates by longer duration of treatment and early deeper response Clinical Lymphoma Myeloma and Leukemia. 2015;15:e74 Prognostic value of the inverse platelet-to-lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated upfront with a novel-agent-containing regimen Clinical Lymphoma Myeloma and Leukemia. 2015;15:e112 Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy Indian Journal of Hematology and Blood Transfusion. 2016;33(1):22-30 Hematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-Line Treatment With A Bortezomib-Based Regimen . 2021; Haematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-line Treatment With a Bortezomib-based Regimen . 2020; Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial Clinical Lymphoma and Myeloma. 2008;8(5):315-317 Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma British Journal of Haematology. 2011;152(5):593-599 Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone Annals of Hematology. 2016;96(3):461-467 |
